$254 Million is the total value of Foresite Capital Management V, LLC's 17 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 35.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $70,334,000 | -38.2% | 2,731,410 | 0.0% | 27.67% | -17.3% | |
| QSI | New | Quantum-Si Incorporated | $28,714,000 | – | 2,342,061 | +100.0% | 11.30% | – |
| ACRS | Aclaris Therapeutics, Inc. | $22,095,000 | -30.3% | 1,258,243 | 0.0% | 8.69% | -6.7% | |
| KNTE | Kinnate Biopharma Inc. | $20,370,000 | -25.3% | 875,001 | 0.0% | 8.01% | -0.0% | |
| GMTX | Gemini Therapeutics, Inc. | $15,755,000 | -52.3% | 2,435,125 | 0.0% | 6.20% | -36.1% | |
| RLAY | Relay Therapeutics, Inc. | $14,636,000 | +5.8% | 400,000 | 0.0% | 5.76% | +41.6% | |
| ALXO | Sell | ALX Oncology Holdings Inc. | $12,642,000 | -46.4% | 231,200 | -27.8% | 4.97% | -28.3% |
| NRIX | Nurix Therapeutics, Inc. | $11,979,000 | -14.7% | 451,522 | 0.0% | 4.71% | +14.2% | |
| HIMS | Hims & Hers Health, Inc. | $11,510,000 | -17.7% | 1,056,922 | 0.0% | 4.53% | +10.1% | |
| PHICU | Population Health Investment Co., Inc.unit | $9,744,000 | +1.0% | 960,000 | 0.0% | 3.83% | +35.2% | |
| ME | New | 23andMe Holding Co. | $8,183,000 | – | 700,000 | +100.0% | 3.22% | – |
| PHVS | Sell | Pharvaris N.V. | $6,784,000 | -63.5% | 364,142 | -45.2% | 2.67% | -51.1% |
| FSII | FS Development Corp. II | $6,013,000 | +0.2% | 602,500 | 0.0% | 2.37% | +34.1% | |
| RACB | Research Alliance Corp. II | $5,070,000 | -1.1% | 500,000 | 0.0% | 2.00% | +32.4% | |
| BCTG | BCTG Acquisition Corp. | $4,552,000 | +2.3% | 400,000 | 0.0% | 1.79% | +36.9% | |
| LHDX | Lucira Health, Inc. | $3,220,000 | -45.1% | 485,000 | 0.0% | 1.27% | -26.6% | |
| HLXA | Helix Acquisition Corp. | $2,588,000 | +1.5% | 250,000 | 0.0% | 1.02% | +35.7% | |
| IMVT | Exit | Immunovant, Inc. | $0 | – | -50,000 | -100.0% | -0.24% | – |
| Exit | Consonance-HFW Acquisition Corp.unit | $0 | – | -100,000 | -100.0% | -0.29% | – | |
| RACA | Exit | Therapeutics Acquisition Corp | $0 | – | -350,000 | -100.0% | -1.08% | – |
| LSAQ | Exit | LifeSci Acquisition II Corp. | $0 | – | -400,000 | -100.0% | -1.19% | – |
| OLK | Exit | Olink Holding ABsponsored ads | $0 | – | -200,000 | -100.0% | -2.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.